New approaches to localize and sustain drug release in the colon

Objectif

- Development of new dosage forms with the ability to reside for long periods of time in the colon. The newly developed drug carriers will be of two types :
- mucoadhesive polymeric carriers;
- buoyant platforms.
These are designed to deliver two classes of drugs : molecules aimed at local treatment of colon diseases and molecules susceptible to enzymatic degradation such as peptide drugs;
- In vitro and in vivo studies in which the mucoadhesive polymers will be tested as to their ability to function successfully, i.e. adhere to mucosal tissues or float in physiologic fluids;
- In vivo studies to test the viability of the hypothesis that prolongation of residence time in the colon can increase the bioavailability of enzyme susceptible drugs such as peptide drugs;
- Development of an animal model (pig) in which in vivo studies will be performed validates the prolonged residence time of the drug carriers.

Expected outcome

- Localisation of anti-IBD drugs such as salicylate derivatives (5-amino salicylic adic) steroids with local action and hepatic clearance such as budesonide, immunosuppressive agents such as cyclosporine;
- Early stages of colon cancer (when systemic prevention of possible metastasis in the blood comment is still not necessary);
- GI absorption of highly lipophilic molecules;
- GI absorption of peptide drugs or vaccines.
Expected Outcome

- Localisation of anti-IBD drugs such as salicylate derivatives (5-amino salicylic adic) steroids with local action and hepatic clearance such as budesonide, immunosuppressive agents such as cyclosporine;
- Early stages of colon cancer (when systemic prevention of possible metastasis in the blood comment is still not necessary);
- GI absorption of highly lipophilic molecules;
- GI absorption of peptide drugs or vaccines.

Activities

- Polymers blends of Eudragit RL with Polycarbophil (acid form) in different ratios will be prepared and tested for physicochemical and mucoadhesion properties;
- Fabrication of mucoadhesive drug delivery systems. The optimal polymer blends will be formulated into solid dosage forms and tested with two drug markers (at least one of which will be a protein drug) in rats for regional GI mucoadhesion;
- New buoyant dosage forms will be prepared and tested in vitro and in vivo (dogs);
- Novel delivery systems will be prepared and tested for selfbuoyancy properties in bench chemostat;
- The novel formulations will be tested in pigs for increase in dosage form residence time using gamma scintigraphy;
- Pilot human studies will conclude the research.
- Polymers blends of Eudragit RL with Polycarbophil (acid form) in different ratios will be prepared and tested for physicochemical and mucoadhesion properties;
- Fabrication of mucoadhesive drug delivery systems. The optimal polymer blends will be formulated into solid dosage forms and tested with two drug markers (at least one of which will be a protein drug) in rats for regional GI mucoadhesion;
- New buoyant dosage forms will be prepared and tested in vitro and in vivo (dogs);
- Novel delivery systems will be prepared and tested for selfbuoyancy properties in bench chemostat;
- The novel formulations will be tested in pigs for increase in dosage form residence time using gamma scintigraphy;
- Pilot human studies will conclude the research.

Programme(s)

IC-ISC C - Activity (Euratom, EEC) on cooperation in science and technology, 1984-

Thème(s)

Data not available

Appel à propositions

Data not available

Régime de financement

CSC - Cost-sharing contracts

Coordinateur

University of Nottingham

Contribution de l’UE

Aucune donnée

Adresse

University Park
NG7 2RD Nottingham
Royaume-Uni

Coût total